Larry Haimovitch

Why ReVision Optics Shut Down

A Look Behind ReVision Optics’ Shuttered Door

By Larry Haimovitch and Richard Mark Kirkner Someday for some company, the business of selling corneal inlays to treat presbyopia could be very lucrative, but that day is not today and that company is not ReVision Optics, which abruptly closed its doors last week. ReVision Optics developed the Raindrop Near...

Read More
How Tweaks to Iluvien Agreement Benefit Alimera, pSivida

How Tweaks to Iluvien Agreement Benefit Alimera, pSivida

A longstanding distribution agreement between Alimera Sciences and pSivida for the Iluvien intravitreal implant has been amended, much to the apparent benefit of both companies. Iluvien is an implant that delivers daily microdoses of the corticosteroid fluocinolone over three years to patients with diabetic macular edema (DME). The original agreement...

Read More

What’s Behind the Heat-up in Glaucoma Innovation

Kicking off the sixth annual Glaucoma 360-New Horizons Forum held recently in San Francisco, co-founder and co-chair Adrienne Graves boldly proclaimed, “Glaucoma is hot.” However, over the past few years, glaucoma has been anything but hot. Stone cold may be more like it. Innovation had been sorely lacking and the...

Read More
As Novartis Ponders Alcon’s Sale, Who Is Best Owner?

As Novartis Ponders Alcon’s Sale, Who Is Best Owner?

So when does a rumor cease being a rumor and become a reality? It remains to be seen whether all the recent and persistent rumors about Novartis selling Alcon will come to fruition, but they received a big credibility boost when its chairman, Joerg Reinhardt, said in an interview recently...

Read More
Corneal Inlays Garnering Attention – and Investment - Eye On Innovation Article - Healthegy

Corneal Inlays Garnering Attention – & Investment

Recent positive reports about two FDA-approved corneal inlays may yet give this market sector a boost heading into 2017. Irvine, CA-based AcuFocus was the first to gain FDA approval (April 2015), and while sales of its Kamra inlay have not exactly skyrocketed, the company received a massive vote of confidence...

Read More
OIS Eye On Innovation Article - How Hot Is MIGS? - Healthegy

How Hot is MIGS?

The string of approvals and acquisitions in the microinvasive glaucoma surgery space has been one of ophthalmology’s more promising stories. The news shone a bright stage light on what had been one of ophthalmology’s lower-profile sectors. But just how hot is MIGS getting? Followers of the MIGS space have likely...

Read More

Is Surprising Raindrop Approval a Sign of Friendlier FDA?

One of the takeaways that ophthalmic innovators might be reading into the unexpected and somewhat sudden approval of the Raindrop Near Vision Inlay is that the FDA may be becoming more responsive and industry friendly. But that wouldn’t be the only takeaway. The FDA surprised virtually everyone in the ophthalmic...

Read More
Iridex Makes Its Move in Glaucoma - Eye On Innovation Article

Iridex Makes its Move in Glaucoma

Over the past couple of years, there has been no shortage of positive news about the glaucoma space. While minimally invasive glaucoma surgery (MIGS) has totally captured the limelight, Iridex Corp. has quietly begun to build momentum with its Cyclo G6 laser. Iridex has a more than 30-year track record...

Read More
How MIGS is Remaking the Glaucoma Market - Ophthalmology Innovation Summit 2015

How MIGS is Remaking the Glaucoma Market

Glaucoma is a chronic degenerative disease whose incidence increases significantly with age. According to the World Health Organization, it is the second leading cause of blindness in the world. Estimates put the total number of suspected cases of glaucoma at over 60 million worldwide. Glaucoma medications, which generate about $5...

Read More
Glaucoma Getting a Wake-Up Call

Glaucoma Getting a Wake-Up Call

SAN FRANCISCO — Thanks to a pending boom in minimally invasive glaucoma surgery (MIGS) devices, the global glaucoma device market is poised to come out of its long slumber and triple over the next five years, participants at the fifth annual “Glaucoma 360-New Horizons Forum” heard. Sponsored by the non-profit...

Read More
Calhoun Vision Stages Turnaround

Calhoun Vision Stages Turnaround

Medtech companies in ophthalmology have made some significant strides in recent months. Second Sight and Glaukos, of course, staged IPOs in their pursuit of revolutionary ophthalmic devices. Oculeve excited Dry Eye leader Allergan enough to warrant a significant acquisition offer, bringing the highly promising neurostim device in-house where it may...

Read More
Were Glaukos’ IPO Investors Irrationally or Rightly Exuberant?

Were Glaukos’ IPO Investors Irrationally or Rightly Exuberant?

OIS Hot Shot Glaukos Corp. (NASDAQ—GKOS) raised over $100 million in an initial public offering (IPO) that highlighted extraordinary demand for ophthalmology’s minimally invasive glaucoma surgery (MIGS) market leader. In its initial SEC filing, Glaukos had proposed selling 5.4 million shares in the range $13 to $15 per share. With...

Read More